Antimicrobial Activity of Cyclic-Monomeric and Dimeric Derivatives of the Snail-Derived Peptide Cm-p5 against Viral and Multidrug-Resistant Bacterial Strains

González-García, Melaine; Morales-Vicente, Fidel; Pico, Erbio Diaz; Garay, Hilda; Rivera, Daniel G.; Grieshober, Mark; Olari, Lia Raluca; Groß, Rüdiger; Conzelmann, Carina; Krüger, Franziska; Zech, Fabian; Bozzo, Caterina Prelli; Müller, Janis A.; Zelikin, Alexander N.; Raber, Heinz Fabian; Kubiczek, Dennis; Rosenau, Frank; Münch, Jan; Stenger, Steffen; Spellerberg, Barbara; Franco, Octávio L.; Rodríguez, Armando A.; Ständker, Ludger; Otero‐González, Anselmo J.

doi:10.3390/biom11050745

Cited by 9 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with the previously obtained results, the L. monocytogenes Δ mptD mutant showed a significantly decreased sensitivity toward synthetic Angicin, when compared to the wildtype. To verify that this effect was specific for Angicin, the susceptibility of L. monocytogenes Δ mptD toward other antilisterial peptides, like β2-microglobulin (B2M) or Cm-p5 was examined ( Holch et al, 2020 ; González-García et al, 2021 , p. 5; Supplementary Figure 1 ). However, inhibition zones against L. monocytogenes and its isogenic mptD mutant were identical for these AMPs.…”

Section: Resultsmentioning

confidence: 99%

The bacteriocin Angicin interferes with bacterial membrane integrity through interaction with the mannose phosphotransferase system

et al. 2022

Self Cite

View full text Add to dashboard Cite

In a natural environment, bacteria are members of multispecies communities. To compete with rival species, bacteria produce antimicrobial peptides (AMPs), called bacteriocins. Bacteriocins are small, cationic, ribosomally synthesized peptides, which normally inhibit closely related species of the producing organism. Bacteriocin production is best studied in lactic bacteria (LAB). Streptococcus anginosus, belonging to LAB, produces the potent bacteriocin Angicin, which shows inhibitory activity against other streptococci, Listeria monocytogenes and vancomycin resistant Enterococcus faecium (VRE). Furthermore, Angicin shows a high resistance toward pH changes and heat, rendering it an interesting candidate for food preservation or clinical applications. The inhibitory activity of Angicin depends on the presence of a mannose phosphotransferase system (Man-PTS) in target cells, since L. monocytogenes harboring a deletion in an extracellular loop of this system is no longer sensitive to Angicin. Furthermore, we demonstrated by liposome leakage and pHluorin assays that Angicin destroys membrane integrity but shows only low cytotoxicity against human cell lines. In conclusion, we show that Angicin has a detrimental effect on the membrane of target organisms by using the Man-PTS as a receptor.

show abstract

Section: Resultsmentioning

confidence: 99%

The bacteriocin Angicin interferes with bacterial membrane integrity through interaction with the mannose phosphotransferase system

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Within this time frame, there were two (1.46%) studies in 2015 [ 6 , 7 ], 15 (10.95%) studies in 2016 [ 1 , 3 , 8 - 20 ], 19 (13.87%) studies in 2017 [ 21 - 39 ], 27 (19.71%) studies in 2018 [ 40 - 64 ], 23 (16.79%) studies in 2019 [ 2 , 65 - 86 ], 24 (17.52%) studies in 2020 [ 87 - 110 ], and 27 (19.70%) studies in 2021 [ 111 - 137 ]. Regarding the type of studies reviewed, 121 (88.32%) studies included in vitro elements [ 2 , 3 , 6 - 12 , 14 - 20 , 23 - 26 , 28 - 42 , 44 - 47 , 49 - 56 , 58 - 64 , 66 , 68 - 72 , 74 - 77 , 79 , 80 , 82 - 87 , 89 - 118 , 120 , 122 - 133 , 135 - 139 ] and 23 (16.79%) in vivo [ 2 , 13 , 15 , 18 , 22 , 25 , 27 , 28 , 37 , 43 , 48 , 56 , 62 , 67 , 73 , 78 , 81 , 100 , …”

Section: Reviewmentioning

confidence: 99%

A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV

Lince¹,

DeMario²,

Yang³

et al. 2023

Cureus

View full text Add to dashboard Cite

Drug-resistant variants of herpes simplex viruses (HSV) have been reported that are not effectively treated with first-line antiviral agents. The objective of this study was to evaluate available literature on the possible efficacy of second-line treatments in HSV and the use of second-line treatments in HSV strains that are resistant to first-line treatments. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a final search was conducted in six databases on November 5, 2021 for all relevant literature using terms related to antiviral resistance, herpes, and HSV. Eligible manuscripts were required to report the presence of an existing or proposed second-line treatment for HSV-1, HSV-2, or varicella zoster virus (VZV); have full-text English-language access; and potentially reduce the rate of antiviral resistance. Following screening, 137 articles were included in qualitative synthesis. Of the included studies, articles that examined the relationship between viral resistance to first-line treatments and potential second-line treatments in HSV were included. The Cochrane risk-of-bias tool for randomized trials was used to assess risk of bias. Due to the heterogeneity of study designs, a meta-analysis of the studies was not performed. The dates in which accepted studies were published spanned from 2015-2021. In terms of sample characteristics, the majority (72.26%) of studies used Vero cells. When looking at the viruses on which the interventions were tested, the majority (84.67%) used HSV-1, with (34.31%) of these studies reporting testing on resistant HSV strains. Regarding the effectiveness of the proposed interventions, 91.97% were effective as potential managements for resistant strains of HSV. Of the papers reviewed, nectin in 2.19% of the reviews had efficacy as a second-line treatments in HSV, amenamevir in 2.19%, methanol extract in 2.19%, monoclonal antibodies in 1.46%, arbidol in 1.46%, siRNA swarms in 1.46%, Cucumis melo sulfated pectin in 1.46%, and components from Olea europeae in 1.46%. In addition to this griffithsin in 1.46% was effective, Morus alba L. in 1.46%, using nucleosides in 1.46%, botryosphaeran in 1.46%, monoterpenes in 1.46%, almond skin extracts in 1.46%, bortezomib in 1.46%, flavonoid compounds in 1.46%, andessential oils were effective in 1.46%, but not effective in 0.73%. The available literature reviewed consistently supports the existence and potentiality of second-line treatments for HSV strains that are resistant to first-line treatments. Immunocompromised patients have been noted to be the population most often affected by drug-resistant variants of HSV. Subsequently, we found that HSV infections in this patient population are challenging to manage clinically effectively. The goal of this systematic review is to provide additional information to patients on the potentiality of second-line treatment in HSV strains resistant to first-line treatments, especially those who are immunocompromised. All patients,...

show abstract

“… 39 AMPs like nisin, cecropins and defensins have proven antimicrobial activity for both Gram-positive and Gram-negative microorganisms. 19 , 32 , 33 , 40 …”

Section: Antimicrobial Peptides: Multidrug-resistant Microbial Therap...mentioning

confidence: 99%

“…39 AMPs like nisin, cecropins and defensins have proven antimicrobial activity for both Gram-positive and Gram-negative microorganisms. 19,32,33,40 Antifungal peptides (AFPs) are excellent alternative drug candidates for combating pathogenic fungi, including Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, Histoplasma capsulatum and molds. Many of the AFPs can also inhibit the growth of A. flavus, which is the causative agent of aflatoxins.…”

Section: Classification Of Antimicrobial Peptides Based On Their Acti...mentioning

confidence: 99%

Multidrug-Resistant Microbial Therapy Using Antimicrobial Peptides and the CRISPR/Cas9 System

Getahun¹,

Ali²,

Taye³

et al. 2022

VMRR

View full text Add to dashboard Cite

The emergence and spread of multidrug-resistant microbes become a serious threat to animal and human health globally because of their less responsiveness to conventional antimicrobial therapy. Multidrug-resistant microbial infection poses higher morbidity and mortality rate with significant economic losses. Currently, antimicrobial peptides and the CRISPR/Cas9 system are explored as alternative therapy to circumvent the challenges of multidrug-resistant organisms. Antimicrobial peptides are small molecular weight, cationic peptides extracted from all living organisms. It is a promising drug candidate for the treatment of multidrug-resistant microbes by direct microbial killing or indirectly modulating the innate immune system. The CRISPR/Cas9 system is another novel antimicrobial alternative used to manage multidrug-resistant microbial infection. It is a versatile gene-editing tool that uses engineered single guide RNA for targeted gene recognition and the Cas9 enzyme for the destruction of target nucleic acids. Both the CRISPR/Cas9 system and antimicrobial peptides were used to successfully treat nosocomial infections caused by ESKAPE pathogens, which developed resistance to various antimicrobials. Despite, their valuable roles in multidrug-resistant microbial treatments, both the antimicrobial peptides and the CRISPR/Cas systems have various limitations like toxicity, instability, and incurring high manufacturing costs. Thus, this review paper gives detailed explanations of the roles of the CRISPR/Cas9 system and antimicrobial peptides in circumventing the challenges of multidrug-resistant microbial infections, its limitation and prospects in clinical applications.

show abstract

Antimicrobial Activity of Cyclic-Monomeric and Dimeric Derivatives of the Snail-Derived Peptide Cm-p5 against Viral and Multidrug-Resistant Bacterial Strains

Cited by 9 publications

References 37 publications

The bacteriocin Angicin interferes with bacterial membrane integrity through interaction with the mannose phosphotransferase system

The bacteriocin Angicin interferes with bacterial membrane integrity through interaction with the mannose phosphotransferase system

A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV

Multidrug-Resistant Microbial Therapy Using Antimicrobial Peptides and the CRISPR/Cas9 System

Contact Info

Product

Resources

About